Search Press Releases

 Search

Caregiver Action Network Honors Mental Health Awareness Month with Website for Families of Loved Ones with Mental Health Issues

May 23, 2018   |   
I Care 1 Cares

WASHINGTON, D.C. – May 23, 2018 – Families of loved ones with mental illness are about to get more help thanks to Caregiver Action Network (CAN). Today Caregiver Action Network is launching a brand new website, Blueprint for Families of a Loved One with Mental Health Issues, to help families address some of the challenges they face when caring for a mentally ill family member.

Read More

Tags: Blueprint for Caregivers Mental Health Awareness

ProterixBio Presents Results from Multiple COPD Clinical Studies at the American Thoracic Society International Conference

May 23, 2018   |   
I Care 1 Cares

BILLERICA, MA – May 22, 2018 – ProterixBio, Inc. today announced that results from three clinical studies of subjects with chronic obstructive pulmonary disease (COPD) were presented at the American Thoracic Society International Conference this week.

One presentation, “Prospective Evaluation of Algorithms Based on Blood Biomarkers as Guides for COPD Assessment and Risk Stratification,” highlighted that blood biomarker based algorithms associate with propensity for future exacerbations, indicating that advanced molecular assessments may improve the characterization of a patient’s disease activity in advance of potentially avoidable events.

Read More

Tags: Proterix Bio

Verona Pharma Presented Clinical Data at ATS 2018 that Further Highlights RPL554 as a First-in-Class Treatment for COPD

May 22, 2018   |   
I Care 1 Cares

LONDON, UK – May 22, 2018 – Verona Pharma plc, a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, today presented Phase 2a and pharmacokinetic data from two clinical trials evaluating its lead product candidate, RPL554, in chronic obstructive pulmonary disease (COPD) at the American Thoracic Society International Conference (ATS 2018), in San Diego. Results from these trials were previously reported by Verona Pharma on September 7, 2017 and September 27, 2017, respectively.

Read More

Tags: Verona

Circassia Announces Positive Data Presented at 2018 American Thoracic Society Conference from Tudorza® Phase IV and Duaklir® Phase III Studies

May 22, 2018   |   
I Care 1 Cares

OXFORD, UK – May 22, 2018 – Circassia Pharmaceuticals plc, a specialty pharmaceutical company focused on respiratory disease, today announces the presentation of positive clinical data from the Tudorza® Pressair® phase IV ASCENT study and Duaklir® Pressair® phase III AMPLIFY study at the American Thoracic Society (ATS) 2018 International Conference currently being held in San Diego, CA.

Read More

Tags: ASCENT Circassia COPD drug therapy

Verona Pharma to Present Clinical Trial Data of RPL554 for COPD Maintenance Treatment at American Thoracic Society 2018 International Conference

May 09, 2018   |   
I Care 1 Cares

LONDON, UK – May 9, 2018 – Verona Pharma, a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces that it will present data from its chronic obstructive pulmonary disease (COPD) clinical trial program with lead product candidate, RPL554, at the American Thoracic Society International Conference (ATS) in San Diego, CA from May 18-23, 2018.

RPL554 is a first-in-class, inhaled, dual inhibitor of the enzymes phosphodiesterase 3 and 4 designed to have anti-inflammatory as well as bronchodilator properties, and is currently in development for the maintenance treatment of COPD and for the treatment of cystic fibrosis.

Details of the Company’s poster presentations are listed below and the abstracts are available to the public online at the American Thoracic Society website.

Read More

COPD Foundation Launches O2VERLAP Study

May 08, 2018   |   
I Care 1 Cares

WASHINGTON, D.C. – May 8, 2018 – The COPD Foundation today announced the launch of the O2VERLAP study in partnership with the American Sleep Apnea Association (ASAA). This research initiative is designed to measure the effectiveness of patient-centered proactive care methods on adherence to medical device therapies in patients diagnosed with both chronic obstructive pulmonary disease (COPD) and obstructive sleep apnea (OSA). COPD is a deadly respiratory disease that affects 30 million Americans and is characterized by wheezing and breathlessness; 10-15% of COPD patients also live with OSA, a condition that causes brief stops in breathing throughout the night.

“Patients who have both COPD and OSA experience considerable complications of these diseases — far more than COPD or OSA individually. Improving adherence to interventions is critical to improving outcomes in those who live with these conditions,” said Barbara Yawn, MD, Chief Scientific Officer at the COPD Foundation.

Read More

Tags: COPD O2verlap overlap syndrome sleep apnea

Once-daily Trelegy Ellipta gains expanded indication in the US for the treatment of patients with COPD

April 24, 2018   |   
I Care 2 Cares

LONDON, UK – April 24, 2018 – GlaxoSmithKline plc and Innoviva, Inc. today announced that the US Food and Drug Administration (FDA) has approved an expanded indication for Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol ‘FF/UMEC/VI’), which means this medicine can now be used by US physicians to treat a broader population of chronic obstructive pulmonary disease (COPD) patients with airflow limitation or who have experienced an acute worsening of respiratory symptoms.

The new indication is for the long-term, once-daily, maintenance treatment of airflow obstruction in patients with COPD, including chronic bronchitis and/or emphysema. It is also indicated to reduce exacerbations of COPD in patients with a history of exacerbations. It is not indicated for relief of acute bronchospasm or for the treatment of asthma.

Read More

Tags: Trelegy Ellipta

Landmark IMPACT study published in NEJM shows significant benefits of Trelegy Ellipta for patients with COPD

April 19, 2018   |   
I Care 2 Cares

LONDON, UK – April 19, 2018 – GlaxoSmithKline and Innoviva, Inc. has announced the publication in the New England Journal of Medicine (NEJM) of the landmark IMPACT study, one of the biggest ever conducted in patients with chronic obstructive pulmonary disease (COPD) with a history of exacerbation.

In the study, Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol, ‘FF/UMEC/VI’ 100/62.5/25mcg) achieved superiority to members of two different classes of dual combination therapy, Relvar/Breo (FF/VI) and Anoro (UMEC/VI), on the primary endpoint of reduction in the annual rate of on-treatment moderate/severe exacerbations (p<0.001) and a range of other clinically important outcomes, including lung function and health-related quality of life.

Read More

Tags: IMPACT study Trelegy Ellipta

Leadership Change at COPD Foundation Corinne Costa Davis Named Interim CEO

April 16, 2018   |   
I Care 2 Cares

WASHINGTON, D.C. – April 16, 2018 – The COPD Foundation announced today that Corinne Costa Davis has been named Interim Chief Executive Officer, effective immediately. She replaces Craig Kephart who had served in the role since May 2016. Mr. Kephart will be returning to the private sector where he previously held senior leadership positions in the specialty pharmacy arena. The COPD Foundation thanks Craig for his contributions and for continuing the legacy started by founder John Walsh in 2004.

“We are grateful to Craig for his service to the COPD Foundation. Craig stepped in following the untimely loss of John Walsh and carried us through a difficult, transitional time. We wish him well in his new endeavors” said Byron Thomashow, MD and Chairman of the Board of Directors.

The COPD Foundation welcomes Corinne Costa Davis as its new Interim Chief Executive Officer. She was elected to the COPD Foundation’s Board of Directors in 2017 and headed the Foundation’s Development Committee.

Read More

Verona Pharma Reports Positive Top-Line Data from Phase 2b Clinical Trial of RPL554 for Maintenance Treatment of COPD

March 26, 2018   |   
I Care 4 Cares

LONDON, UK – March 26, 2018 – Verona Pharma plc, a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces today positive top-line data from its Phase 2b study evaluating RPL554, a first-in-class, inhaled, dual inhibitor of the enzymes phosphodiesterase 3 and 4 with bronchodilator and anti-inflammatory properties, as a maintenance treatment for chronic obstructive pulmonary disease (COPD).

The study met its primary endpoint, with RPL554 producing a clinically and statistically significant improvement in peak forced expiratory volume in one second (FEV1) at four weeks in patients with moderate-to-severe COPD compared to placebo. Furthermore, the peak FEV1 was significantly improved at all time points over the four weeks of dosing. Secondary endpoints measuring 12 hour average FEV1, COPD symptoms and Quality of Life were also met and support the potential clinical benefits of RPL554 for the treatment of COPD.

The four-week, double-blind, placebo-controlled, parallel group, Phase 2b multicenter European study performed in the out-patient setting evaluated the efficacy, safety, and dose-response of nebulized RPL554 administered twice-daily as a maintenance treatment for COPD in 403 patients with moderate-to-severe COPD. There were four dosing arms of RPL554 (0.75 mg, 1.5 mg, 3.0 mg and 6.0 mg) in the study in addition to placebo and patients were required to withhold use of regular long-acting bronchodilator therapy for the duration of the study.

Read More

Tags: Verona

Free Webinar "COPD and Women: Gender Disparities Worldwide"

March 07, 2018   |   
I Care 3 Cares

WASHINGTON, D.C. – March 8, 2018 – This International Women’s Day, the COPD Foundation will host a free webinar “COPD and Women: Gender Disparities Worldwide” to address the critical impact chronic obstructive pulmonary disease (COPD) has on women and their greater communities. COPD is an umbrella term for a number of respiratory diseases such as emphysema and chronic bronchitis. The disease is characterized by an increasing inability to breathe and affects more than 200 million globally. COPD has historically been considered a “man’s disease,” however over the past 50 years COPD deaths have increased by only 27% in men versus 400% in women.

Our experts, Dr. MeiLan Han, MD, MS, is Associate Professor of Medicine in the Division of Pulmonary and Critical Care at the University of Michigan, as well as Kristen Willard and Stephanie Williams of the COPD Foundation will provide insights into the gaps in care worldwide. “If you ask a physician to envision a COPD patient, in their mind they see a man, because men are more likely to have been smokers for long periods of time," says Dr. Han.

Read More

Tags: International Women's Day

COPD Foundation Recognizes Honorees During Annual Awards Ceremony

November 03, 2017   |   
I Care 10 Cares

NEW YORK CITY, NY – November 3, 2017 – Patient advocacy and research organization COPD Foundation paid tribute to a special group of individuals and organizations at its Annual Awards Celebration in New York City on November 2, 2017. Held at the historic Metropolitan Club, the event’s honorees were recognized for their commitment to COPD awareness and the advancement of a COPD cure. Their advocacy, research, outreach, and care-delivery efforts have helped to build a broad understanding of the disease while improving lives of those directly affected. Gerard Turino, M.D., founding chairman of the COPD Foundation, received the highest honor for his achievements in COPD research and care delivery.

“Dr. Turino is known as an innovator and thought-leader in the field of COPD research,” says Craig Kephart, Chief Executive Officer of the COPD Foundation. “His work spans many decades, pioneering the way we look at the progression and treatment of COPD today. He has been at the forefront of this effort and has played an integral part in the formation and growth of the COPD Foundation.”

Read More

Tags: Annual Awards Ceremony

1 2 3 4 5 6 7 8 9 10 ... 22

Join Us on COPD360social

Sign In to Participate
Or register to become a member